United Therapeutics (UTHR) EPS (Weighted Average and Diluted) (2009 - 2026)

United Therapeutics has disclosed EPS (Weighted Average and Diluted) across 18 years of filings, most recently posting $5.82 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $5.82, down 12.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.08 (up 7.97% YoY), and the FY2025 annual result was $27.86, up 13.07% from the prior year.
• EPS (Weighted Average and Diluted) came in at $5.82 for Q1 2026 at United Therapeutics, down from $7.69 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $7.69 in Q4 2025 to a low of $2.41 in Q2 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $5.82 (2026), against an average of $5.48.
• Peak annual rise in EPS (Weighted Average and Diluted) reached 724.59% in 2022, while the deepest fall reached 33.97% in 2022.
• United Therapeutics' EPS (Weighted Average and Diluted) stood at $2.65 in 2022, then jumped by 63.4% to $4.33 in 2023, then surged by 43.42% to $6.21 in 2024, then climbed by 23.83% to $7.69 in 2025, then fell by 24.32% to $5.82 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $5.82 (Q1 2026), $7.69 (Q4 2025), and $7.16 (Q3 2025), per Business Quant data.